Camurus AB
CAMX
Rank in Stocks
#4010
Camurus AB (publ), a biopharmaceutical company, develops and commercializes... Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; and Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Share Price
$68.24
Market Cap
$4.06B
Change (1 day)
0.97%
Change (1 year)
-2.05%
Country
SE
Trade Camurus AB (CAMX)
Category
Healthcare
P/E ratio for Camurus AB (CAMX)
P/E ratio as of 2026 TTM: 0
According to Camurus AB latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Camurus AB from 2011 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2025 | 49.60 | -35.23% |
| 2024 | 76.57 | 10.69% |
| 2023 | 69.18 | -72.37% |
| 2022 | 250.39 | -375.80% |
| 2021 | -90.79 | 54.65% |
| 2020 | -58.70 | 333.11% |
| 2019 | -13.55 | 30.62% |
| 2018 | -10.38 | -62.11% |
| 2017 | -27.39 | -48.82% |
| 2016 | -53.51 | 335.39% |
| 2015 | -12.29 | -124.04% |
| 2014 | 51.13 | 105.26% |
| 2013 | 24.91 | -86.58% |
| 2012 | 185.63 | 0.00% |
| 2011 | 0.00 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | - |
US
|
|
| -28.36 | - |
US
|
|
| -24.57 | - |
AU
|
|
| 30.33 | - |
NL
|
|
| - | - |
CH
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.